Slide

An understanding of disease processes drives innovation in medicine

Slide

«A thinker sees his own actions as experiments
and questions, as attempts to find out something.
Success and failure are for him answers above all.»

Slide

«There is one thing even more vital to science than intelligent
methods; and that is the sincere desire to find out the truth,
whatever it may be.»

– Charles Pierce

Slide

«Every great advance in science has issued
from a new audacity of imagination»

– John Dewey

Slide

«Somewhere, something incredible is waiting to be known»

– Carl Sagan

Slide

«There is nothing which can better deserve your patronage
than the promotion of science and literature. Knowledge is in every country the surest basis of public happiness.»

– George Washington

Slide

«Learn from yesterday, live for today, hope for tomorrow
The important thing is to not stop questioning.»

– Albert Einstein

Welcome

Welcome to the website of the CellCOM Research Group. Our group is a translational and clinical research group within the Institute of Biomedical Research of A Coruña (INIBIC), part of the University Hospital Complex A Coruña, which provides a strong clinical basis for laboratory-based research. Our approaches combine in vitro, ex vivo and in vivo models to conduct pre-clinical studies in age-related diseases and cancer. Our group is a multidisciplinary team that includes basic scientists (predoctoral, postdoctoral fellows and technicians) and clinical researchers such as pathologists, dermatologists, radiologists and surgeons.

Our aims are to understand the physiopathology of connexin-linked diseases (cancer, inflammation, tissue degeneration), to design molecules and new drugs that modulate the activity of specific targets and to identify novel markers of disease prevention, diagnosis and disease management.

We are focused on understanding the role of connexins and pannexins in osteoarthritis, skin wound healing in oncological patients, metastasis and resistance to targeted cancer therapies and immunotherapies. Our final goal is to identify effective therapeutic targets to design specific and successful therapeutic approaches to treat these disorders.